Latest Conference Articles

In another major study comparing TAVR to surgery, outcomes were similar.

The phase 3b MUSCA trial reported positive results for mepolizumab.

Jay Jin, MD, PhD, Mayo Clinic, shared the results from his team's case series surrounding unexpected bradycardia effect from epinephrine administration.

Anthony S. Fauci, MD, Director, National Institute of Allergy and Infectious Diseases (NIAID), shared with MD Magazine what the main theme would be in his keynote address at the AAAAI 2017 meeting in Atlanta, GA: emerging and reemerging infections, a perpetual challenge.

Only a small percentage of people who think they have a penicillin allergy actually do.

How safe are anti-inflammatory medications for children?

A chlamydia vaccine would cut infection rates, but cost millions.

Katia Boven, MD, Head of Clinical Development and Global Medical Affairs, Infectious Diseases, Janssen, discussed results and impact of the SWORD clinical trial involving the investigational two-drug combination being as effective as the three or four regimens as maintenance therapy in HIV patients who have already achieved viral suppression.

"Even though we have a lot of drugs, because of the resistance profile of their virus, they don't have a lot of options, so what these results mean for the most vulnerable of our patients is that they have access now to a new class of drugs," Emu concluded.

Among a large sample of Veterans Affairs health care patients with peripheral artery disease, researchers found African Americans were 43% more likely to lose a limb to amputation--and it is likely not because of socioeconomic or behavioral factors.

In just over a year, Praluent has shown benefits in helping patients lower their cholesterol level. Despite the progress, there have also been some challenges.

One of the biggest challenges cardiologists face is treating patients with atrial fibrillation who are undergoing percutaneous coronary intervention, particularly when it comes to prescribing anticoagulants.

An analysis of thousands of patients in Germany taken from a national registry found interventional procedures more dangerous than surgery for severe symptomatic aortic valve stenosis. But there may have been confounding factors.

Systemic atherosclerosis causes peripheral artery disease, and these patients are at risk of cardiovascular death and stroke.

The mysterious sudden deaths of apparently healthy people, some young and engaged in sports, could be explained by mutations uncovered by a Canada research team.

Are healthcare workers who wear glasses or contacts more likely to get colds and flu? Researchers at Johns Hopkins report on a study with intriguing findings.

In a sign of the growing global problem of drug resistance, researchers from Ohio reported a steady increase in the percentages of cases of gonorrhea that did not respond to the usual antibiotics.

Could the interaction of Zika virus with similar flaviviruses like Dengue and Chikungunya be the reason why Zika virus has turned so virulent after decades of being a minor illness?

The mortality rate of AMD patients who received a bevacizumab injection 3 or 6 months after stroke was, in the study’s words, “worrying” compared to the rate of those who did not.

Explaining diabetic macular edema to patients can be a challenge in itself. Going further to explain the injection process can take even more care for eye care professionals.

Difluprednate, a steroid stronger than prednisolone, was recently tested for treatment of macular edema and vitritis in cases of posterior/intermediate uveitis, and its impact was noticeable.

At The North American Menopause Society 27th Annual Meeting (NAMS) in Orlando, Florida, Janet Carpenter, PhD, RN, Indiana University discussed her latest research in nonhomonal alternatives for women experiencing hot flashes including a clinical hypnosis protocol.

At The North American Menopause Society 27th Annual meeting (NAMS), Holly Thomas, MD, MS, University of Pittsburgh, discussed her program of research mainly focuses on how sex changes for women as they move through midlife and into older age.

As Peter Schnatz, DO, Reading Health System, completes his term as President of NAMS, he reflected on the initial goals he'd had before assuming his position. His primary initiative was to bring the best care they could to menopausal women. Schnatz said they'd been working really hard on reopening the conversation of the use and utilization of hormonal therapy.

Peter Schnatz, DO, Reading Health System, current President of The North American Menopause Society (NAMS), spoke about his presidential address, which discussed breast arterial calcification (BAC) and the association with risk factors and atheroscleratic cardiovascular disease.

There is limited data in this population, but some research says that women shouldn't be starting the therapy after the age of 60. However, hormone therapies offer bone protection, which opens the door discussion on usage.

Do osteoporosis medications impact sexual function? That's what researchers aimed to find in a study presented at The North American Menopause Society 27th Annual Meeting (NAMS 2016) in Orlando, Florida.

Geography, age, and time are factors that contribute to the likelihood that a woman is being treated for menopause, according to new research out of Pfizer Inc.